Search
News & Events
Childhood cancer story: How Rennae's child's cancer diagnosis affected her familyRennae's son Samuel was diagnosed with stage 4 neuroblastoma 13 years ago, and was originally given a 20% chance of survival. She bravely shares their story.
News & Events
Funding boost for childhood cancer research projectsProjects to improve outcomes for leukaemia patients and reduce skin cancer rates in young Aboriginal people have received funding through Cancer Council WA.
News & Events
Immunotherapy drug dramatically improves survival for babies with rare leukaemiaA pilot clinical study, led in Australia by a The Kids Research Institute Australia and Perth Children's Hospital researcher, has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.
News & Events
Homeward bound: The Kids Research Institute Australia researcher taking on scientific leadership challengeThe Kids Research Institute Australia researcher, Dr Anya Jones, will join some of the world’s brightest female scientists after being selected to take part in a global project to amplify the voices of women in science leadership.
News & Events
New childhood brain tumour drugs to be testedIt is the kids he treats in his role as a paediatric oncologist that motivate Dr Nick Gottardo in his work as a The Kids Research Institute Australia cancer researcher.
News & Events
Research sheds new light on childhood Leukaemia treatmentA The Kids study examining drug resistance in leukaemia patients has shed new light on why some treatments may be more effective than others.
Research
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-inThere is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma.
Research
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy ResponsesImmunotherapies have revolutionized cancer treatment. In particular, immune checkpoint therapy (ICT) leads to durable responses in some patients with some cancers. However, the majority of treated patients do not respond. Understanding immune mechanisms that underlie responsiveness to ICT will help identify predictive biomarkers of response and develop treatments to convert non-responding patients to responding ones. ICT primarily acts at the level of adaptive immunity. The specificity of adaptive immune cells, such as T and B cells, is determined by antigen-specific receptors.
Research
Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocolThe outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.
Research
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemiaT cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with inferior outcome compared with that of B cell ALL. Here, we show that Runt-related transcription factor 2 (RUNX2) was upregulated in high-risk T-ALL with KMT2A rearrangements (KMT2A-R) or an immature immunophenotype. In KMT2A-R cells, we identified RUNX2 as a direct target of the KMT2A chimeras, where it reciprocally bound the KMT2A promoter, establishing a regulatory feed-forward mechanism.